Pescara

• VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM … Recruiting
  2024-520119-41-00 4 2023-01-15 Previously untreated patients with diagnosis of HCL
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 5 2022-12-06 Acute Myeloid Leukemia
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k … Recruiting
  2023-510240-20-00 4 2022-10-05 Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com … Recruiting
  2023-510515-19-00 5 2020-11-27 Higher-risk-myelodysplastic syndromes
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 5 2020-09-24 Favorable-intermediate-risk Acute Myeloid Leukemia
• Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c … Recruiting
  2023-505901-17-00 5 2020-04-24 Acute Myeloid Leukemia (LMA) with FLT3 mutation
• Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c … Recruiting
  2023-510516-39-00 4 2019-10-30 Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL … Ended recruitment
  2024-511627-34-00 4 2024-10-17 Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2022-502238-22-00 5 2024-05-14 Ulcerative Colitis
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Ended recruitment
  2024-517424-18-00 6 2022-05-10 Patients with EGFR mutant NSCLC according to TP53 mutational status
• Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi … Ended recruitment
  2023-510432-36-00 4 2022-03-01 Acute Myeloid Leukemia with NPM1 mutation
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa … Ended recruitment
  2024-518304-53-00 5 2022-02-02 Relapsed or Refractory Multiple Myeloma (RRMM)
• Study aimed at evaluating the efficacy of a combination treatment (decitabine and venetoclax) in patients with Acute Myeliode Leukemia who a … Ended recruitment
  2023-510241-16-00 4 2021-12-03 Acute Myeloid Leukemia secondary to myeloproliferative neoplasms
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph … Ended recruitment
  2024-511636-27-00 5 2021-12-01 Follicular Lymphoma
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and … Ended recruitment
  2023-508968-30-00 5 2021-09-08 Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended recruitment
  2024-514473-21-00 5 2021-06-21 Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa … Ended recruitment
  2024-516868-28-00 4 2021-05-04 Ph+ Acute Lymphoblastic Leukemia

Showing 25–48 of 61 trials